Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

521 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer.
Pezaro C, Mukherji D, Tunariu N, Cassidy AM, Omlin A, Bianchini D, Seed G, Reid AH, Olmos D, de Bono JS, Attard G. Pezaro C, et al. Among authors: de bono js. Br J Cancer. 2013 Jul 23;109(2):325-31. doi: 10.1038/bjc.2013.340. Epub 2013 Jun 27. Br J Cancer. 2013. PMID: 23807167 Free PMC article. Clinical Trial.
Reversing resistance to targeted therapy.
Vidal L, Attard G, Kaye S, De Bono J. Vidal L, et al. J Chemother. 2004 Nov;16 Suppl 4:7-12. doi: 10.1179/joc.2004.16.Supplement-1.7. J Chemother. 2004. PMID: 15688600 Review.
Making sense of antisense.
Vidal L, Blagden S, Attard G, de Bono J. Vidal L, et al. Eur J Cancer. 2005 Dec;41(18):2812-8. doi: 10.1016/j.ejca.2005.06.029. Epub 2005 Nov 9. Eur J Cancer. 2005. PMID: 16289851 Review.
Update on tubulin-binding agents.
Attard G, Greystoke A, Kaye S, De Bono J. Attard G, et al. Pathol Biol (Paris). 2006 Mar;54(2):72-84. doi: 10.1016/j.patbio.2005.03.003. Pathol Biol (Paris). 2006. PMID: 16545633 Review.
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours.
Greystoke A, Blagden S, Thomas AL, Scott E, Attard G, Molife R, Vidal L, Pacey S, Sarkar D, Jenner A, De-Bono JS, Steward W. Greystoke A, et al. Among authors: de bono js. Ann Oncol. 2006 Aug;17(8):1313-9. doi: 10.1093/annonc/mdl097. Epub 2006 May 25. Ann Oncol. 2006. PMID: 16728482 Free article. Clinical Trial.
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days.
Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, Cassidy J, Gianella-Borradori A, Judson I, Twelves C. Benson C, et al. Br J Cancer. 2007 Jan 15;96(1):29-37. doi: 10.1038/sj.bjc.6603509. Epub 2006 Dec 19. Br J Cancer. 2007. PMID: 17179992 Free PMC article. Clinical Trial.
521 results